CliffBio
small molecule

CIMETIDINE

CIMETIDINE

Loss of exclusivity—loss of exclusivity
CompanyCycle Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameCIMETIDINE
Active ingredientCIMETIDINE
Strength400MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 1994
Marketing statusDISCN

More from Cycle Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CIMETIDINE patent cliff — loss of exclusivity — | CliffBio